IAS | December 09, 2021
Integral Ad Science (Nasdaq: IAS), a global leader in digital media quality, today announced an advanced integration with Mediaocean, providing a new level of automated campaign management. Now media buyers and planners can seamlessly set up, launch, and adjust their digital campaigns within Mediaocean buyer workflow (Prisma) and automatically populate this information within IAS Signal. Initially available to select advertisers, this enhanced integration will launch globally in early 2022.
"Since launching IAS Signal, we've accelerated our product innovation and expanded critical partnerships, including our work with Mediaocean, to give advertisers the latest tools to manage digital media quality," said Lisa Utzschneider, CEO, IAS. "Speed is critical in our business, and this integration will be transformational for advertisers looking to launch campaigns faster while aligning to media quality standards."
Now advertisers working with both IAS and Mediaocean can quickly and easily activate their campaigns, all in one place. Within the Mediaocean platform, advertisers can:
Use automatic campaign creation tools to enter information just once, launch faster, and focus more time on optimization.
Maintain and easily adjust campaign settings, such as media partners or run dates, while in-flight to appear in both platforms.
Reduce time spent on campaign launch and billing from days to minutes.
"We're thrilled to extend our partnership with IAS, making it even easier for our joint customers to manage their campaigns," said Ben Kartzman, COO, Mediaocean. "With this integration, we're continuing to help advertisers control their marketing investments and optimize business outcomes."
With more than $200 billion in annualized media spend managed through Mediaocean, the integration with IAS Signal means advertisers can manage their investments more efficiently.
About Integral Ad Science
Integral Ad Science (IAS) is a global leader in digital media quality. IAS makes every impression count, ensuring that ads are viewable by real people, in safe and suitable environments, activating contextual targeting, and driving supply path optimization. Our mission is to be the global benchmark for trust and transparency in digital media quality for the world's leading brands, publishers, and platforms. We do this through data-driven technologies with actionable real-time signals and insight. Founded in 2009 and headquartered in New York, IAS works with thousands of top advertisers and premium publishers worldwide. For more information, visit integralads.com.
Mediaocean is the mission-critical platform for omnichannel advertising. With more than $200 billion in annualized media spend managed through its software, Mediaocean connects brands, agencies, media, technology, and data. Using AI and machine learning technology to control marketing investments and optimize business outcomes, Mediaocean powers campaigns from planning, buying, ad serving, and creative personalization to analysis, optimization, invoices, and payments. Mediaocean employs 1,500 staff across 30 global offices and supports over 100,000 people using its products
AD TECH AND MARTECH
Tomi.ai | June 24, 2021
Real estate, automobile, and financial services all have lengthy and offline sales cycles, and digital advertising does not work well in these industries. Because the real-world assets remain offline, the temptation for advertisers is to buy leads and clicks, which may increase customer acquisition costs. People browse, but they mainly purchase offline.
Tomi, a new startup, intends to solve this problem by analyzing a user's activity on a company's website (through a tracking pixel combined with ad APIs and CRMs) to assist businesses in reaching customers more effectively in the manner of an e-commerce business.
It has already raised a $1 million initial round from Begin Capital and the Phystech Leadership Fund.
Tomi was founded by Konstantin Bayandin, a former senior director of digital marketing and technology at Compass and chief marketing officer at Ozon, called "Russia's Amazon." It competes with comparable AdTech firms such as Anytrack, Sociaro, Meetotis, Alytics, and Postclick.
The difference, according to Bayandin, is that Tomi "focuses on offline conversions and works with various ad channels, including Facebook, Instagram, and Google."
"Real-estate firms would love to use internet advertising to sell their inventory, but it turns out to be too costly and difficult," says Bayandin. In addition, people like browsing but rarely convert, and the majority of these transactions take place offline. As a result, real-estate clients are unsure of how to optimize for their real buyers. Tomi uses machine learning to examine how real buyers navigate the website and improve ad campaigns for conversions."
The context for all of this is that, with Apple discontinuing IDFA, Google intending to delete third-party cookies from its Chrome browser, and the newest iOS 14.5 update enabling users to opt-out of "personalized ads," the whole advertising industry is in flux, necessitating the development of new technologies. Tomi, according to Bayandin, is a member of this new wave of AdTech.
Q BioMed Inc. | November 21, 2020
Q BioMed Inc., announces that the advertising effort for Strontium89 (Strontium Chloride Sr-89 Injection, USP), the Company's FDA affirmed treatment that objectives agonizing bone metastases, has been chosen for consideration in Ads of the World, a cautiously curated chronicle of the world's best innovative missions. The choice models for consideration directs that lone the most elevated type of innovative work gets distributed.
Strontium89, the radiotherapy with almost 30 years of demonstrated outcomes in soothing excruciating bone metastases, is accessible in the US from Q BioMed. In the Strontium89 urgent preliminary, the same number of as 79% of patients had relief from discomfort with Strontium89, and twice the same number of patients treated with Strontium89 had no agony for a very long time contrasted and fake treatment. Further, new agony locales were less successive in patients treated with Strontium891,2.